Both the companies hope to make use of their resources to promote vital university clinical development.
The agreement will make use of IntelliCell’s expertise in separation of adipose tissue into stromal vascular fraction containing stem cells and Numoda’s innovative patented platforms and reporting engines.
IntelliCell’s manufacturing technology is believed to reduce the cost of producing autologous stem cells without expansion.
Numoda chairman Mary Schaheen said stem cells’ research is being done in 55 universities and the collaboration would help researchers by providing access to their technologies.